International Journal for Innovative Engineering and Management Research
PEER REVIEWED OPEN ACCESS INTERNATIONAL JOURNAL
www.ijiemr.org

A STUDY OF CLINICAL EVALUATION OF FORMULATION FACTORS INFLUENCING TOWARDS DRUG DELIVERY SYSTEM

KRISHAN DEV PARASHAR, DR. NILESH M. MAHAJAN

DESIGNATION-RESEARCH SCHOLAR SUNRISE UNIVERSITY ALWAR
DESIGNATION- (PROFESSOR) SUNRISE UNIVERSITY ALWAR

ABSTRACT

The purpose of determining the physicochemical characteristics, release kinetics, and ocular biocompatibility of the newly created formulation, the research used both in vitro and in vivo evaluations. In order to assess the chemical stability of the PPAR-Gamma agonist inside the formulation, a number of different analytical methods were used. These techniques included spectroscopy and chromatography. In addition, preclinical experiments were carried out in order to evaluate the overall effectiveness of the improved formulation in the context of relevant ocular disease models. According to the results of our research, the PPAR-Gamma topical formulation that was developed demonstrated improved ocular bioavailability and prolonged therapeutic benefits, along with a significant decrease in the likelihood of adverse events occurring. When it comes to enhancing the therapeutic advantages of PPAR-Gamma agonists in ocular applications, the research highlights how important it is to have a formulation approach that has been properly devised. A unique method to harnessing the therapeutic potential of PPAR-Gamma agonists while assuring better safety and effectiveness is offered by the topical formulation that was created. This formulation represents a substantial development in ocular drug delivery systems. Several ocular disorders that are related with inflammation and neovascularization might potentially be treated with the help of this study, which provides vital insights for future improvements in ocular medication delivery and offers hope for the treatment of these diseases.

KEYWORDS: Clinical Evaluation, Formulation Factors, Drug Delivery System, physicochemical characteristics, PPAR-Gamma, disease models

INTRODUCTION

In this article, the theoretical framework that is offered is not limited to laboratory settings; rather, it encompasses both preclinical and clinical studies instead. When it comes to

verifying the safety and effectiveness of enhanced PPAR-gamma formulations, preclinical research, which include both in vitro and in vivo investigations, become a natural development. For the purpose of evaluation, parameters such as pharmacokinetics, tissue distribution, and therapeutic effectiveness become focus points. In the process of translating preclinical discoveries into clinical trials, a crucial crossroads is reached, when theoretical concerns and real-world applications meet. The clinical studies serve as the basis for testing the theoretical framework in human patients. These trials also give insights into the practicability and scalability of the improved PPAR-gamma formulations. An attempt that encompasses molecular pharmacology, ocular physiology, and pharmaceutical sciences, the optimization of PPAR-gamma topical formulations for better safety and efficacy in ophthalmic drug delivery is a complex undertaking that aims to improve the safety and effectiveness of drug administration. This theoretical framework, which is based on the study of the molecular basis of PPAR-gamma in ocular treatment, the navigation of the hurdles given by ocular barriers, and the manipulation of formulation parameters, offers researchers a road map that allows them to journey into unexplored territory of ocular drug delivery. The potential of PPAR-gamma agonists to transform ophthalmic medicine is driving the promise of new therapies for ocular illnesses, which is looming big as we continue down this road.

FORMULATION FACTORS INFLUENCING SAFETY AND EFFICACY

The formulation parameters of ocular drug delivery systems play a crucial part in determining the safety and effectiveness of these systems, which in turn has a significant influence on the results of therapeutic interventions. During the process of optimizing formulations for ocular applications, researchers are required to negotiate a complex interplay of factors. These variables include medication selection, delivery methods, penetration enhancers, and concerns of biocompatibility and safety. In order to achieve the delicate balance between enhancing medication bioavailability inside the eye and reducing undesirable effects, it is essential that these formulation elements work together in a synergistic manner. This will ensure that the therapeutic intervention is not only successful but also safe for patients.

An essential component of the formulation is the selection of the medicine itself, which has a substantial impact on both the effectiveness and the safety of the medication. During the selection process, the physicochemical qualities, pharmacokinetics, and therapeutic profile of

the medicine are all taken into careful account. When it comes to ophthalmic formulations, the ideal medicine should have appropriate solubility in the vehicle that is used, stability that allows it to tolerate ocular conditions, and a therapeutic concentration range that can be obtained inside the tissues that are being targeted. In addition, the safety profile of the medicine, which may take into account the possibility of causing irritation or toxicity to the eyes, has to be properly reviewed. The pharmacological properties of the medicine serve as the foundation for the formulation design process, which in turn lays the groundwork for following considerations.

Another essential component of formulation is the drug delivery system, which provides a variety of platforms for optimizing drug release and increasing ocular bioavailability. Drug delivery may be accomplished via the use of nanoemulsions, liposomes, microspheres, and other carriers. These carriers have the ability to influence aspects such as release kinetics and tissue distribution. Both the unique needs of the medicine and the ocular tissues that are being targeted should be taken into consideration when selecting the delivery mechanism. As an instance, formulations with continuous release may be helpful for the treatment of chronic problems, while formulations with quick release may be chosen for the treatment of acute interventions. Additionally, the design of these systems must take into account aspects such as stability, convenience of administration, and patient compliance. This is done to guarantee that the delivery system selected is in accordance with both the therapeutic aims and the clinical practicality of the treatment.

Penetration enhancers are a kind of formulation component that has been developed expressly for the purpose of overcoming ocular barriers and increasing the rate at which medications are able to pass through tissues and connective tissues. When selecting these enhancers, which are often added in formulations to increase medication bioavailability, it is essential to exercise caution in order to strike a balance between effectiveness and safety. Surfactants, cyclodextrins, and bioadhesive polymers are all examples of different types of penetration enhancers. Each of these types of enhancers has its own set of benefits as well as possible downsides. The evaluation of the safety profiles of penetration enhancers, the assessment of their influence on ocular tissues, and the consideration of their compatibility with other formulation components are all components of the theoretical framework for improving penetration enhancer strategies. To achieve improved medication penetration without

compromising the integrity of ocular barriers or causing discomfort is a problem that must be overcome.

In the process of developing ophthalmic formulations, biocompatibility and safety concerns are taking precedence as the most important factors to take into account. The degree to which excipients, preservatives, and other formulation components are biocompatible has a direct impact on the way in which they interact with ocular tissues and, as a result, the overall safety profile of the drug delivery system. The maintenance of sterility, the prevention of microbiological contamination, and the avoidance of allergic responses or irritation are of the utmost importance. Although preservatives are essential for preventing the development of microorganisms, they must be selected with caution in order to avoid causing eye toxicity. In a similar vein, the osmolarity of formulations is a factor that influences ocular tolerability. Solutions that are extremely hypertonic or hypotonic have the potential to cause pain or unpleasant effects. In order to establish a theoretical foundation for biocompatibility, it is necessary to conduct a thorough investigation of every component of the formulation, evaluate the effect that it has on the tissues of the eye, and make certain that the formulation is in accordance with the physiological circumstances of the eye.

Additionally, the total formulation has to take into account the method of administration as well as the dosage form. The pharmacokinetics and therapeutic effectiveness of the medicine are affected by the manner in which it is supplied, namely whether it is applied topically, administered intravitreally, or implanted using sustained-release technology. When it comes to characteristics such as residence duration, convenience of administration, and patient adherence, the dose form, which might include eye drops, ointments, or inserts, plays a significant aspect. When it comes to these elements, theoretical considerations require having a grasp of the distinct issues that are linked with each route of administration and dosage form. This understanding enables the formulation to overcome obstacles that are special to the modality that has been selected.

Because the formulation elements that influence the safety and effectiveness of ocular drug delivery systems are complex and linked, a nuanced approach is required in order to produce the best possible therapeutic results. A full grasp of drug characteristics, delivery mechanisms, penetration enhancers, and concerns of biocompatibility and safety are the

cornerstones of the theoretical framework that underpins the formulation of ocular medications.

The problem of maintaining a delicate equilibrium between increasing bioavailability inside the eye and minimizing the risk of deleterious consequences is one that is always present. The possibility for creating new, safe, and effective ocular drug delivery systems is emerging as researchers continue to dive deeper into the complexities of these formulation aspects. This holds the promise of bringing about breakthroughs in the treatment of a variety of eye disorders.

One of the most important aspects of drug selection is the selection of an effective PPAR-γ agonist that has good pharmacokinetic features and minimal adverse effects. The solubility, stability, and bioavailability of the drug in ocular tissues should all be taken into consideration throughout the selecting process.

Drug Delivery methods there are a variety of drug delivery methods that may enhance the stability and prolonged release of PPAR-γ agonists. Some examples of these systems are Nano emulsions, liposomes, and microspheres. As part of the theoretical framework, it is necessary to evaluate the benefits and drawbacks of various medication delivery methods in order to get best results.

Penetration Enhancers It is of the utmost importance to have a thorough understanding of the function that penetration enhancers play in promoting drug absorption from one eye to another. The evaluation of the safety and effectiveness of penetration enhancers in PPAR-γ formulations is a theoretical concern that must be taken into account.

Regarding biocompatibility and safety, it is of utmost importance that PPAR-γ formulations have a good safety profile. The evaluation of the biocompatibility of excipients and the identification of the potential for eye irritation or toxicity should be the primary focus of theoretical research.

PRECLINICAL AND CLINICAL EVALUATION

In the context of ocular drug delivery systems targeting Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-γ), the preclinical and clinical assessment of pharmacological

interventions is a crucial crossroads when theoretical frameworks shift into empirical validation. This is especially true in the area of PPAR-γ treatment. In order to evaluate the safety, effectiveness, and pharmacokinetics of the improved PPAR-γ topical formulations, this complicated procedure requires a number of research that are both methodical and thorough. These investigations range from in vitro studies to human clinical trials. During this phase, the translational bridge that connects theoretical considerations to real-world applications is strengthened. This phase also serves to guide the advancement of prospective therapies from laboratory settings to the bedside.

The earliest stages in confirming the theoretical framework devised for PPAR-γ formulations constitute the preclinical assessment, which marks the beginning of the process. Researchers are able to investigate essential features such as drug release kinetics, stability, and cellular interactions via the use of in vitro experiments, which serve as the foundational layer. Cell culture models, especially those that resemble ocular tissues and barriers, provide insights into the behavior of the formulation when it is subjected to controlled settings. These preliminary tests provide crucial information on the potential effectiveness of the PPAR-γ agonist, its cytotoxicity, and the formulation's capability to cross ocular barriers. Moreover, the data obtained in vitro are used as a foundation for in vivo preclinical research, which are often carried out using animal models. Drug pharmacokinetics, biodistribution, and preliminary evaluations of therapeutic effectiveness are all topics that are investigated in these investigations. The selection of animal models is of the utmost importance, with species-specific ocular anatomy and physiology, as well as possible physiological changes in drug metabolism, being taken into account. In this way, preclinical assessment functions as a crucible, a place where theoretical predictions are put to the test, modified, and verified before moving on to the more complicated environment of human trials.

When moving from preclinical research to clinical trials, it is necessary to carefully plan human trials in order to evaluate the effectiveness and safety of the treatment while adhering to ethical constraints. Phase I clinical studies are crucial in determining the safety profile of the PPAR-γ topical formulation in human participants. These trials are the first stage in the evaluation process. These clinical studies, which are normally carried out on a limited group of healthy volunteers, are designed to ascertain the maximum dosage that can be tolerated, as well as the pharmacokinetics and any early warning signals of toxicity. When it comes to

refining dosing regimens and improving the safety characteristics of the formulation, the data that is obtained during Phase I trials is quite significant. This data lays the framework for following stages of the evaluation process.

Phase II clinical trials are an important transition because when they are conducted, the emphasis turns to determining whether or not the formulation is effective in treating the ocular illness that is being addressed. The PPAR-γ formulation is administered to larger patient groups, which often include people who are afflicted by the particular ocular ailment, in order to assess the therapeutic effect of the therapeutic intervention.

Within the context of these clinical studies, a comprehensive analysis of clinical endpoints, biomarkers, and patient-reported outcomes is necessary. In the context of real-world clinical circumstances, the predictions made by the theoretical framework with respect to the regulation of inflammatory responses, angiogenesis, or oxidative stress are put to the test. Phase II studies, which are presently being conducted, provide the possibility of collecting more safety data from a patient group that is more varied.

It is the final validation phase for the PPAR-γ topical formulation to undergo Phase III clinical trials, which are characterized by greater sample numbers and a randomized controlled design. In addition to determining the formulation's comparative effectiveness in comparison to established therapies or placebos, the primary focus is on establishing that the formulation is both efficacious and safe in a wide range of patient populations.

An examination of the theoretical concerns that were used to influence the construction of the formulation is carried out within the setting of the actual world, with a particular focus on reproducibility and generalizability. It is possible to evaluate the robustness of the theoretical framework by determining whether or not the formulation is capable of consistently delivering therapeutic advantages to a wide range of patients.

During the whole of the clinical assessment process, it is of the utmost importance to monitor and record any adverse events that occur. In order to discover any unanticipated adverse effects or toxicities, stringent safety examinations, which may include ocular and systemic evaluations, are carried out. The results of these evaluations provide essential information

that may be used to enhance the safety profile of the PPAR-γ formulation and provide guidance for prospective adjustments.

Post-marketing monitoring, which is an extension of the clinical assessment phase, is still an essential component in order to constantly evaluate the effectiveness and safety of the PPAR-γ formulation in clinical settings that are representative of the real world. The gathering of data over an extended period of time helps in the identification of uncommon adverse occurrences and offers continuous safety assurance. The iterative aspect of the medication development process is reinforced throughout this phase, which also makes it possible to make alterations based on experiences collected from the real world and new data.

In the realm of therapeutic applications, the preclinical and clinical assessment of PPAR-γ topical formulations serves as a bridge between theoretical breakthroughs and practical implementations. In vitro evaluations and animal models are examples of the kind of preclinical research that give the basic evidence for the safety and effectiveness of a treatment. The theoretical framework is subjected to rigorous testing during the course of clinical studies, which go from Phase I to Phase III and include a wide range of patient groups.

The completion of these studies not only provides evidence that the theoretical foundations are sound, but it also prepares the path for the formulation to be included into the treatment of patients in mainstream clinical settings. The promise of an improved PPAR-γ topical formulation for better safety and effectiveness in ocular medication delivery is getting closer to being realized via the efforts of researchers who are navigating the complex terrain of preclinical and clinical evaluations.

DRUG DELIVERY SYSTEM

When it comes to pharmacological interventions, the topic of drug delivery systems comprises a wide variety of novel techniques that are aimed at maximizing the therapeutic effectiveness, patient safety, and patient compliance. A medication delivery system, in its most fundamental sense, functions as the medium via which therapeutic chemicals are carried to the specific location inside the body where they are intended to exert their effects. In order to create and build systems that are capable of controlling the release, distribution, and

pharmacokinetics of pharmaceuticals, this diverse field incorporates ideas from the fields of pharmaceutical sciences, materials science, engineering, and biology. The overriding objective is to improve the patient experience while simultaneously reducing the number of adverse effects occurring and enhancing the overall treatment results.

The conventional method of administering drugs often comprises the oral or parenteral administration of pharmaceuticals in standard dose forms such as tablets, capsules, or injections. This method is also known as the traditional technique. Despite the fact that these techniques have been shown to be effective, they are not necessarily the most effective means of delivering focused and prolonged drug release. On the other hand, drug delivery systems give a platform for precise control over drug kinetics, which enables them to propose answers to problems that are associated with bioavailability, medication stability, and patient adherence.

Controlled-release or sustained-release formulations are considered to be one of the most basic groups of drug delivery technologies. These systems are intended to regulate the pace at which pharmaceuticals are released over a long period of time, so ensuring that therapeutic concentrations remain within the range that is needed. When it comes to drugs that need to be administered often, this is especially beneficial since it improves patient compliance and reduces changes in drug levels. Matrix systems, reservoir systems, and osmotic systems are all examples of controlled-release formulations that may be modified to produce precise release kinetics. Other kinds of controlled-release formulations include osmotic systems.

A paradigm change in medication delivery has occurred as a result of the introduction of nanoparticles and microspheres within the area of controlled-release systems since their introduction. Nanoparticles, which normally vary in size from one to one hundred nanometers, and microspheres, which range in size from one to one thousand micrometers, each provide certain benefits that are not found in other materials. These benefits include increased drug solubility, longer release, and the possibility of tailored administration. Due to the fact that nanoparticles are so tiny, they are able to take use of passive or active targeting mechanisms in order to deliver medications selectively to certain tissues or cells. This helps to reduce the amount of systemic exposure and adverse effects that occur.

Liposomes are an additional category of drug delivery devices that are distinguished by their use of a lipid bilayer structure. This diverse platform for drug administration is made possible by the fact that these vesicles are capable of encapsulating both hydrophilic and lipophilic medicines. Through the use of liposomes, drug stability may be improved, circulation duration can be extended, and drug absorption by target cells can be enhanced. Furthermore, they provide the possibility of triggered release in response to external stimuli, such as changes in pH or temperature, which further refines the control over the characteristics of drug release kinetics.

In order to overcome the difficulties that are connected with the delivery of genetic material, the development of specialized drug delivery systems has been prompted by the introduction of medicines that are based on nucleic acids and genes. Some examples of delivery methods that are specifically designed for the transport of nucleic acids include viral vectors, lipoplexes, and polyplexes. The fragile genetic material is protected from destruction by these systems, which also enhance cellular absorption and permit regulated release. As a result, the therapeutic potential of gene-based therapies is increased.

When it comes to the administration of drugs via the eye, there are specific obstacles that emerge as a result of the intricate anatomy and physiology of the eye. Traditional eye drops have limits when it comes to producing sustained medication concentrations. Additionally, the cornea, conjunctiva, and blood-retinal barrier all create obstacles that further complicate the process of drug administration to the posterior portion of the eye. Nanoparticles, liposomes, and inserts are some examples of the ophthalmic medication delivery methods that have emerged as potential and effective strategic solutions. Nanoemulsions, for instance, have the ability to improve the ocular penetration of hydrophobic medicines and increase their solubility. Due to the fact that they are biocompatible, liposomes provide a prolonged release of the medicine as well as increased drug retention on the surface of the eye.

When it comes to administering medication directly into the vitreous fluid of the eye, intravitreal injections are a particular method of such administration. This method is very useful for the treatment of retinal conditions including diabetic retinopathy and age-related macular degeneration, which are both conditions that affect the retina. The intravitreal injection technique is very successful; but, due to its invasive nature, it is imperative that

special attention be given to the patient's safety and comfort. Implants that provide sustained-release medication have developed as an alternative. These implants allow for regulated drug release over a prolonged period of time and reduce the number of injections that are required.

Taking use of the skin as a channel for medication absorption, the transdermal drug delivery system is yet another unique strategy that has been developed. There are a number of benefits associated with transdermal patches, including continuous medication release, the avoidance of first-pass metabolism, and greater patient compliance. It is standard practice to use these systems for the delivery of medications that have a limited therapeutic index, situations in which it is essential to maintain a consistent drug level in order to ensure both effectiveness and safety.

CONCLUSION

As the area of drug delivery continues to undergo development, it is becoming more important for multidisciplinary teams consisting of doctors, chemists, pharmacologists, and engineers to work together. In order to bridge the gap between bench side innovation and clinical application, it is necessary to make deliberate efforts to address regulatory issues, safety evaluations, and the scalability of innovative delivery methods. By acting in this manner, researchers have the ability to speed up the process of translating ground-breaking findings into observable benefits in patient care. The quest of greater drug retention and penetration represents a disruptive trajectory in the field of pharmaceutical research, which is set to change the landscape of therapeutic interventions. Through the process of deciphering the complexity of medication delivery, we are able to unleash the potential to transform treatment paradigms, therefore providing patients with treatments that are more effective, targeted, and customized. The dedication to upgrading drug delivery technology reflects a common vision for improving the effectiveness and accuracy of therapeutic treatments across a wide range of medical disciplines at a time when we are on the verge of entering a new era in the field of medicine. Furthermore, as we negotiate the ever-changing world of customized medicine, the modification of drug delivery systems based on unique patient profiles has a tremendous amount of promise. An optimization of therapy regimens is made possible with the incorporation of precision medicine concepts into medication development and delivery. This optimization takes into account genetic variances, metabolic differences, and the

particular requirements of each individual patient. This paradigm shift toward tailored treatment techniques is in line with the overarching objective of maximizing therapeutic effectiveness while simultaneously lowering the possibility of adverse effects.

REFERENCES

1. Al, R., Silverstain, J.H., Amemiya, S., Zeitler, P., Klingensmith G.J., 2009. Type 2 Diabetes in Children and Adolescent. Pediatric Diabetes, 10, 17-32.

2. Alghananim, Alaa & Ozalp, Yildiz & Mesut, Burcu & Serakinci, Nedime & Ozsoy, Yildiz & Güngör, Sevgi. (2020). A Solid Ultra Fine Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) of Deferasirox for Improved Solubility: Optimization, Characterization, and In Vitro Cytotoxicity Studies. Pharmaceuticals. 13. 162. 10.3390/ph13080162.

3. Ali, Z.H., 2011. Health and knowledge progress among diabetic patients after implementation of a Nursing Care program based on their profile. Journal of diabetes and metabolism, 2(2), 121.

4. Allen, D.A., Yaqoob, M.M. and Harwood, S.M., 2005. Mechanisms of high glucoseinduced apoptosis and its relationship to diabetic complications. The Journal of nutritional biochemistry, 16(12), 705-713.

5. Almeida, H., Amaral, M. H., Loba, P., Lobo, J. M. S., 2013. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discovery Today, 1-13.

6. Alruwaili, Nabil & Zafar, Ameeduzzafar & Imam, Syed & Alharbi, Khalid & Alotaibi, Nasser & Alshehri, Sultan & Alhakamy, Nabil & Alzarea, Abdulaziz & Afzal, Muhammad & Elmowafy, Mohammed. (2020). Stimulus Responsive Ocular Gentamycin-Ferrying Chitosan Nanoparticles Hydrogel: Formulation Optimization, Ocular Safety and Antibacterial Assessment. International Journal of Nanomedicine. Volume 15. 4717-4737. 10.2147/IJN.S254763.

7. Alvarado, Helen & Abrego, Guadalupe & Garduno-Ramirez, Maria Luisa & Clares, Beatriz & Calpena, Ana & García, María & Alvarado Bonilla, Helen. (2015). Design and optimization of oleanolic/ursolic acid-loaded nanoplatforms for ocular anti-inflammatory applications. Nanomedicine : nanotechnology, biology, and medicine. 11. 10.1016/j.nano.2015.01.004.

8. Ameeduzzafar, Q.M., Alruwaili, N.K. and Bukhari, S.N.A., 2020. BBDbased development of Itraconazole loaded nanostructured lipid carrier for topical delivery: in vitro evaluation and antimicrobial assessment. Journal of Pharmaceutical Innovation, 1–4.

9. Ameeduzzafar, S.S.I., Syed, N.A.B. and Asgar, A., 2018. Preparation and evaluation of novel chitosan: gelrite ocular system containing besifloxacin for topical treatment of bacterial conjunctivitis: scintigraphy, ocular irritation and retention assessment. Artificial Cells, Nanomedicine, and Biotechnology, 46, 959-967

10. Ayumi, U. O., Yasuo O., Nobuyuki E., 2017. The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells. International Immunopharmacology, 52, 70-76.

11. Barse, R., Kokare, C. and Tagalpallewar, A., 2016. Influence of hydroxypropylmethylcellulose and poloxamer composite on developed ophthalmic in situ gel: Ex vivo and in vivo characterization. Journal of Drug Delivery Science and Technology, 33, 66-74.

12. Bertin, Benjamin & Dubuquoy, Laurent & Colombel, Jean-Frederic & Desreumaux, Pierre. (2013). PPAR-Gamma in Ulcerative Colitis: A Novel Target for Intervention. Current drug targets. 14. 10.2174/13894501113149990162.

13. Bertrand, N. and Leroux, J.C., 2012. The journey of a drug-carrier in the body: an anatomo-physiological perspective. Journal of controlled release, 161(2), 152-163.

14. Bhambere, D., Shirivastava, B., Sharma P. and Gide, P., 2014. Effect of polymer and formulation variables on properties of self-assembled polymeric micellar nanoparticles. Journal of Nanomedicine and Biotherapeutic Discovery, 4(3), 1-11.

15. Bhandwalkar, M.J. and Avachat, A.M., 2013. Thermoreversible nasal in situ gel of venlafaxine hydrochloride: formulation, characterization, and pharmacodynamic evaluation. AAPS Pharmscitech, 14(1), 101-110.

16. Borja, C., Santiago, D., Maria Olga, G.A., 2017. Update on diagnosis and treatment of DR: a consensus guidelines of the working group of ocular health. Journal of ophthalmology, 1-10.